Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
2461 The University of Texas at San Antonio (144349)
Principal Investigator: McHardy, Stanton
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 54,622
Exceeds $250,000 (Is it flagged?): No
Start and End Dates: 9/1/21 - 8/31/23
Restricted Research: YES
Academic Discipline: SCIENCES
Department, Center, School, or Institute: Center For Drug Discovery
Title of Contract, Award, or Gift: Development of antiviral therapies against Nipah and Hendra viruses
Name of Granting or Contracting Agency/Entity:
Southwest Research Institute
CFDA Link: DOD
12.420
Program Title:
none
CFDA Linked: Military Medical Research and Development
Note:
SAMs 1.1.1; The Center for Drug Discovery (CIDD) will collaborate with SWRI, UT Health SA and Texas BioMed to develop novel small molecule therapies for Nipah and Hendra viruses. The in silico and in vitro screening work done at SWRI and Texas BioMed will guide the medicinal chemistry strategy at UTSA and support structure-based drug design, which will be supported by x-ray crystallization studies at UT Health SA. The CIDD at UTSA will be responsible for the design, synthesis and SAR studies to support the goals of the program. Dr. McHardy's lab at UTSA and the CIDD will execute the synthesis routes and prepare the targeted analogs, preparing 10-20 mg of each analog with a targeted purity of >96%, as assessed by 1H NMR and HPLC/MS. Each analog prepared will be registered in the CIDD cheminformatics database and assigned a CIDD compound number. A 5-10 mg sample of the analog will be shipped to our screening collaborator at Texas BioMed (along with a delivery sheet and compound supporting information) and the remaining supply of the compound will be retained as a storage sample in a designated storage area/fridge in the CIDD.
Discussion: No discussion notes